Search research articles
Contact Us
Filters
Showing results (41-50 of 72) with videos related to
Page
of 8
Sort By:
The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS
|
August 13, 2022
Robotic single-port surgery: Preliminary experience in general surgery
Francesco M Bianco, Nicolas H Dreifuss, Betty Chang, et al.
Frontiers in Immunology
|
July 25, 2022
Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase
Yong Du, Ling Lei, Huihua Ding, et al.
Nature Genetics
|
April 4, 2006
Systematic identification of human mitochondrial disease genes through integrative genomics
Sarah Calvo, Mohit Jain, Xiaohui Xie, et al.
Clinical Immunology (Orlando, Fla.)
|
June 1, 2007
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
Polly R Pine, Betty Chang, Nathan Schoettler, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
July 1, 2004
Two distinct coactivators, DRIP/mediator and SRC/p160, are differentially involved in VDR transactivation during keratinocyte differentiation
Yuko Oda, Carina Sihlbom, Robert J Chalkley, et al.
Molecular Endocrinology (Baltimore, Md.)
|
August 2, 2003
Two distinct coactivators, DRIP/mediator and SRC/p160, are differentially involved in vitamin D receptor transactivation during keratinocyte differentiation
Yuko Oda, Carina Sihlbom, Robert J Chalkley, et al.
Journal of Medicinal Chemistry
|
June 27, 2008
Inhibition of the signal transducer and activator of transcription-3 (STAT3) signaling pathway by 4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxylic acid esters
Jun Xu, Derek C Cole, Chao-Pei Betty Chang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 10, 2010
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A Honigberg, Ashley M Smith, Mint Sirisawad, et al.
The Journal of Clinical Investigation
|
November 4, 2015
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma
Rebecca L Goldstein, Shao Ning Yang, Tony Taldone, et al.
Arthritis and Rheumatism
|
April 29, 2008
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus
Frances Rena Bahjat, Polly R Pine, Andrea Reitsma, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 72) with videos related to
Sort By:
Page
of 8
The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS
|
August 13, 2022
Robotic single-port surgery: Preliminary experience in general surgery
Francesco M Bianco, Nicolas H Dreifuss, Betty Chang, et al.
Frontiers in Immunology
|
July 25, 2022
Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase
Yong Du, Ling Lei, Huihua Ding, et al.
Nature Genetics
|
April 4, 2006
Systematic identification of human mitochondrial disease genes through integrative genomics
Sarah Calvo, Mohit Jain, Xiaohui Xie, et al.
Clinical Immunology (Orlando, Fla.)
|
June 1, 2007
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
Polly R Pine, Betty Chang, Nathan Schoettler, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
July 1, 2004
Two distinct coactivators, DRIP/mediator and SRC/p160, are differentially involved in VDR transactivation during keratinocyte differentiation
Yuko Oda, Carina Sihlbom, Robert J Chalkley, et al.
Molecular Endocrinology (Baltimore, Md.)
|
August 2, 2003
Two distinct coactivators, DRIP/mediator and SRC/p160, are differentially involved in vitamin D receptor transactivation during keratinocyte differentiation
Yuko Oda, Carina Sihlbom, Robert J Chalkley, et al.
Journal of Medicinal Chemistry
|
June 27, 2008
Inhibition of the signal transducer and activator of transcription-3 (STAT3) signaling pathway by 4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxylic acid esters
Jun Xu, Derek C Cole, Chao-Pei Betty Chang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 10, 2010
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A Honigberg, Ashley M Smith, Mint Sirisawad, et al.
The Journal of Clinical Investigation
|
November 4, 2015
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma
Rebecca L Goldstein, Shao Ning Yang, Tony Taldone, et al.
Arthritis and Rheumatism
|
April 29, 2008
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus
Frances Rena Bahjat, Polly R Pine, Andrea Reitsma, et al.
Page
of 8